Rinvoq (upadacitinib) is AbbVie’s once-daily oral JAK inhibitor, sold as an extended-release tablet in 15 mg, 30 mg and 45 mg strengths and as an oral solution for children. Per its DailyMed label, revised June 30, 2026, it carries approvals across rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, giant cell arteritis, ulcerative colitis and Crohn’s disease.
It is also one of the more expensive pills in American retail pharmacy. A single 15 mg tablet costs a pharmacy about as much as a month of most generic prescriptions, and unlike Humira there is no biosimilar or generic waiting in the wings to break the price. Every figure below was pulled and verified on September 2, 2026, and this page is about money only, not about whether the drug is right for anyone.
What Does Rinvoq Cost Without Insurance?
AbbVie publishes its own list price, which is unusual and useful. CMS publishes what pharmacies actually pay to acquire the drug through the National Average Drug Acquisition Cost survey, with the rows below effective August 19, 2026 and current as of September 2, 2026. SingleCare publishes what a counter charges. All three are in the table, because they answer three different questions.
| Price point (30-day supply, 15 mg ER) | Low | Average / typical | High |
|---|---|---|---|
| Retail cash, no discount card | $8,947.93 | $8,948 to $9,104 | $9,104 |
| Cash with a discount card | $6,567.81 | $6,568 | $6,568 |
| AbbVie published list price (WAC) | $7,090.41 | $7,090.41 | $7,090.41 |
| CMS NADAC pharmacy acquisition cost | $6,877.10 (30 mg) | $6,878.25 (15 mg) | $6,878.25 |
| 45 mg induction strength, NADAC per 30 days | $13,782.43 | $13,782.43 | $13,782.43 |
| RINVOQ Complete card (commercial insurance only) | $0 | $0 | $0 |
| myAbbVie Assist (income-qualified) | $0 | $0 | $0 |
Note the disagreement on retail, because it is real. SingleCare’s live drug page, updated September 2, 2026, puts the average retail cash price at $8,947.93 for 30 of the 15 mg extended-release tablets. SingleCare’s own explainer article, updated August 5, 2026, says $9,104 for the same quantity and strength. The two pages agree exactly on the discount-card floor of $6,568, which they both attribute to Kroger. Treat $8,948 to $9,104 as the uncovered retail band and $6,568 as the realistic card price, and understand that named-chain prices move from session to session.
List price is not counter price
AbbVie’s cost page states the wholesale acquisition cost for a 30-day supply of Rinvoq is $7,090.41 as of January 6, 2026. CMS NADAC data effective August 19, 2026 puts pharmacy acquisition cost at $229.27495 per 15 mg tablet, which works out to $6,878.25 for 30 once-daily tablets.
Those two independent figures land within about $212 of each other, which tells you the wholesale end of this market is stable and well documented. The gap between that wholesale band and the $8,948 to $9,104 retail quote is pharmacy markup, and it is roughly $2,000 a month.
The 45 mg strength costs double
Per the label, ulcerative colitis uses 45 mg once daily for an 8-week induction period and Crohn’s disease uses it for 12 weeks, before dropping to a 15 mg or 30 mg maintenance dose. NADAC prices the 45 mg tablet at $459.41429, which is $13,782.43 for 30 days of acquisition cost, essentially double the maintenance months.
The 15 mg and 30 mg strengths are priced almost identically per tablet ($229.27 and $229.24), so moving between those two maintenance doses does not change your monthly bill in any meaningful way.
What Drives the Price
There is no generic and no biosimilar. SingleCare’s Rinvoq page states there is no generic version of Rinvoq at this time, and every upadacitinib product FDA lists as marketed carries AbbVie labeling. Nothing on this page can be solved by asking the pharmacist to substitute.
Which strength you are on, and whether you are in an induction phase. A month of 45 mg costs about twice a month of 15 mg at acquisition cost. If you are early in treatment for an inflammatory bowel condition, budget for the higher figure first.
Whether a discount card gets applied. The spread between average retail and the card price is roughly $2,400 to $2,500 a month on the identical bottle. That is the single largest swing available to someone paying cash with no program.
Your insurance type, not your income. The $0 card requires commercial insurance. The free-drug program requires limited or no insurance plus a qualifying income. Medicare enrollees sit in the gap between them, barred from the card by federal rules.
No negotiated Medicare price is coming. CMS has selected 40 drugs across three negotiation cycles. The third-cycle list published January 27, 2026 covers 15 drugs including Xeljanz and Cimzia for prices effective in 2028, and Rinvoq is not on it. Sister drugs get relief, this one does not, at least not on the current schedule.
Cash Price vs. Insurance
If you have commercial insurance that covers Rinvoq, the manufacturer card is the best deal in the room. AbbVie says eligible commercially insured patients may pay as little as $0 a month, with a maximum benefit of $14,000 per calendar year. Against a drug that lists at $7,090.41 a month, that cap covers roughly two months of full list price, so it is meaningful but finite if your plan makes you carry a large share of the cost.
The exclusions are strict and non-negotiable. The card is not available to anyone receiving prescription reimbursement under any federal, state or government-funded program, including Medicare and Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, the Department of Defense or Veterans Affairs. You cannot get around that by asking the pharmacy to run you as a cash payer.
For a truly uninsured patient, paying cash at $6,568 to $9,104 a month is not a plan, it is a placeholder. The number to chase is $0 through myAbbVie Assist. If a pharmacy quotes you something that does not match anything on this page, our fair price checker is a quick sanity test before you hand over a card.
How to Pay Less
-
Apply to myAbbVie Assist before you fill a single prescription. AbbVie’s published income ceiling is $63,840 for a household of one, $86,560 for two, $109,280 for three and $132,000 for four, plus $22,720 for each additional dependent, and the program provides AbbVie medicines free to approved applicants with limited or no coverage. This is worth roughly $80,000 to $110,000 a year, which is more than every other tactic on this list combined.
-
Use the RINVOQ Complete card if you are commercially insured, and watch the cap. The $14,000 per calendar year maximum is generous in absolute terms and small relative to this drug’s list price, so know where you stand by mid-year rather than in December.
-
Never fill without running a discount card. The gap between average retail and the card price is about $2,400 a month on the same bottle. Our comparison of GoodRx vs. SingleCare covers how to check both on the same NDC in a couple of minutes, and both SingleCare pages we read put the floor at the same chain.
-
Ask whether a federally funded health center can dispense it. Community health centers that participate in the 340B drug pricing program buy outpatient drugs at steep statutory discounts and charge on a sliding scale. Our guide to free and sliding-scale clinics explains how to find one and what to ask when you call.
-
Price the induction months separately from maintenance months. If your prescription starts at 45 mg, the first two or three months cost roughly double. Applying for assistance before that phase starts, rather than after, is worth several thousand dollars.
-
Handle the specialist bills that come with the prescription. JAK inhibitors involve regular monitoring visits and labs that are billed separately from the drug. If a rheumatology, dermatology or gastroenterology bill has already arrived, our medical bill negotiation guide covers what to say before you pay it, and blood work costs without insurance prices the lab side.
Bottom Line
Budget $6,568 to $9,104 for a 30-day supply of Rinvoq 15 mg if you walk into a pharmacy and pay cash in September 2026, against AbbVie’s published list price of $7,090.41 and a CMS acquisition cost of $6,878.25. Induction months at 45 mg roughly double that. With no generic and no negotiated Medicare price scheduled, the only routes to a number you can actually live with are the commercial copay card ($0, insurance required) and myAbbVie Assist ($0, income required).
For other brand-only immunology prescriptions priced the same way, see our guides to Otezla, which does have a Medicare negotiated price coming in 2027, plus Skyrizi, Dupixent and Tremfya. Humira is the useful counterexample: it shows what happens to a drug like this one once cheaper equivalents finally reach the shelf.